James Chodosh is an Ophthalmology physician. OpenAlex indexes 604 publications with 16,694 citations (h-index 69); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2211 Lomas Blvd NE
Albuquerque, NM 871062719
Telephone
505-272-6120Provider last certified this registry record 27 Jan 2025.
Clinical trials
- Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
Sponsor: James Chodosh, MD, MPH
- Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)
Sponsor: Massachusetts Eye and Ear Infirmary
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alcon Vision LLCProgram year20251 payment
- Bausch & Lomb Americas Inc.Program year20253 payments
- Bausch & Lomb Americas Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
60.3%Fluoroquinolone Antibacterial42.8%Moxifloxacin100%Part D≥13 patientsMacrolide8.8%Erythromycin100%Part D<11 patients+ 1 more class in this area
Sensory organs
26.8%Corticosteroid13.4%Prednisolone Acetate100%Part D≥13 patientsPolymyxin-class Antibacterial7.7%Polymyxin B Sul-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
6.7%Calcineurin inhibitor6.7%Cequa100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Novel Mechanisms in Adenoviral Ocular Pathogenesis
University of New Mexico Health Scis Ctr
FY2026$1,509,845R01EY021558 - Immunopathogenesis of Adenovirus Keratitis
University of New Mexico Health Scis Ctr
FY2026$319,677R01EY013124 - Novel Mechanisms in Adenoviral Ocular Pathogenesis
University of New Mexico Health Scis Ctr
FY2025$324,063R01EY021558
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”